Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 10 | 2022 | 4148 | 0.620 |
Why?
|
| Peer Review, Research | 1 | 2016 | 66 | 0.520 |
Why?
|
| Finger Injuries | 1 | 2016 | 21 | 0.520 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2013 | 5606 | 0.510 |
Why?
|
| Burns, Chemical | 1 | 2016 | 32 | 0.510 |
Why?
|
| Methylene Blue | 1 | 2016 | 53 | 0.510 |
Why?
|
| Oximetry | 1 | 2016 | 190 | 0.470 |
Why?
|
| Otolaryngology | 1 | 2016 | 146 | 0.470 |
Why?
|
| Parathyroidectomy | 1 | 2016 | 211 | 0.460 |
Why?
|
| Mouth Neoplasms | 3 | 2013 | 736 | 0.430 |
Why?
|
| Oropharynx | 1 | 2013 | 81 | 0.430 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 316 | 0.410 |
Why?
|
| Carcinoma, Ductal | 2 | 2021 | 144 | 0.330 |
Why?
|
| Papillomavirus Infections | 2 | 2014 | 999 | 0.310 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2021 | 141 | 0.300 |
Why?
|
| Parotid Neoplasms | 2 | 2019 | 150 | 0.290 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2021 | 497 | 0.260 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2014 | 1162 | 0.240 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2005 | 109 | 0.220 |
Why?
|
| Students, Medical | 1 | 2008 | 421 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2005 | 248 | 0.210 |
Why?
|
| Cancer Care Facilities | 2 | 2022 | 907 | 0.180 |
Why?
|
| Clinical Competence | 1 | 2008 | 1333 | 0.180 |
Why?
|
| Postoperative Complications | 1 | 2016 | 5681 | 0.180 |
Why?
|
| Smoking | 2 | 2011 | 2549 | 0.170 |
Why?
|
| Mifepristone | 1 | 2019 | 180 | 0.170 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 367 | 0.160 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2019 | 167 | 0.160 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2019 | 82 | 0.160 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 104 | 0.160 |
Why?
|
| Cushing Syndrome | 1 | 2019 | 73 | 0.160 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2019 | 87 | 0.160 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2019 | 207 | 0.160 |
Why?
|
| Surgical Oncology | 1 | 2020 | 212 | 0.150 |
Why?
|
| Matched-Pair Analysis | 3 | 2009 | 100 | 0.140 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2021 | 444 | 0.140 |
Why?
|
| Iodine Radioisotopes | 1 | 2017 | 388 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2017 | 402 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2019 | 854 | 0.120 |
Why?
|
| Parathyroid Neoplasms | 1 | 2016 | 189 | 0.110 |
Why?
|
| Risk Factors | 6 | 2017 | 17867 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 566 | 0.110 |
Why?
|
| RNA, Neoplasm | 2 | 2013 | 805 | 0.110 |
Why?
|
| Polyvinyls | 1 | 2012 | 20 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 623 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2020 | 747 | 0.100 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2012 | 47 | 0.100 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2012 | 30 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 701 | 0.100 |
Why?
|
| Glomus Tumor | 1 | 2012 | 29 | 0.100 |
Why?
|
| Cytodiagnosis | 1 | 2013 | 201 | 0.100 |
Why?
|
| Humans | 24 | 2022 | 270809 | 0.100 |
Why?
|
| Carotid Artery, Internal | 1 | 2012 | 81 | 0.100 |
Why?
|
| Keratin-17 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 1342 | 0.100 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 82 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1608 | 0.090 |
Why?
|
| Adenoma | 1 | 2016 | 738 | 0.090 |
Why?
|
| beta 2-Microglobulin | 1 | 2011 | 188 | 0.090 |
Why?
|
| Odontogenic Tumors | 1 | 2010 | 6 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 2395 | 0.090 |
Why?
|
| Mandibular Neoplasms | 1 | 2010 | 77 | 0.090 |
Why?
|
| Papillomaviridae | 1 | 2013 | 636 | 0.080 |
Why?
|
| Thyroid Neoplasms | 2 | 2019 | 1908 | 0.080 |
Why?
|
| Chicago | 1 | 2008 | 40 | 0.080 |
Why?
|
| Aged | 11 | 2021 | 73641 | 0.080 |
Why?
|
| Cochlear Implantation | 1 | 2009 | 53 | 0.080 |
Why?
|
| Middle Aged | 12 | 2021 | 90570 | 0.080 |
Why?
|
| Speech Perception | 1 | 2009 | 76 | 0.080 |
Why?
|
| Cotinine | 1 | 2008 | 41 | 0.080 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2009 | 155 | 0.070 |
Why?
|
| Universities | 1 | 2008 | 159 | 0.070 |
Why?
|
| Rhinitis | 1 | 2007 | 41 | 0.070 |
Why?
|
| Urban Population | 1 | 2008 | 275 | 0.070 |
Why?
|
| Paranasal Sinuses | 1 | 2007 | 64 | 0.070 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2008 | 128 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 605 | 0.070 |
Why?
|
| Sinusitis | 1 | 2007 | 148 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2012 | 1582 | 0.060 |
Why?
|
| Prevalence | 1 | 2014 | 3395 | 0.060 |
Why?
|
| Adult | 8 | 2021 | 82074 | 0.060 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 10731 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2004 | 5099 | 0.060 |
Why?
|
| Female | 12 | 2021 | 148940 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 1345 | 0.060 |
Why?
|
| Surgical Flaps | 2 | 2008 | 891 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 657 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 31117 | 0.050 |
Why?
|
| Survival Rate | 3 | 2009 | 12535 | 0.050 |
Why?
|
| Male | 12 | 2021 | 128522 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 3841 | 0.050 |
Why?
|
| Age Distribution | 1 | 2004 | 726 | 0.050 |
Why?
|
| Mutation | 1 | 2021 | 15922 | 0.050 |
Why?
|
| Mass Screening | 1 | 2008 | 1547 | 0.040 |
Why?
|
| Occupational Health | 1 | 2020 | 92 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2009 | 5924 | 0.040 |
Why?
|
| Hormone Antagonists | 1 | 2019 | 115 | 0.040 |
Why?
|
| Survivorship | 1 | 2020 | 116 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 4495 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 172 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Biopsy | 2 | 2017 | 3490 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2009 | 6766 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2009 | 13422 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 819 | 0.030 |
Why?
|
| Young Adult | 4 | 2021 | 22255 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2017 | 288 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 557 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2017 | 574 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 1113 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 612 | 0.030 |
Why?
|
| Nitriles | 1 | 2019 | 939 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 841 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2004 | 6234 | 0.030 |
Why?
|
| Survivors | 1 | 2020 | 1022 | 0.030 |
Why?
|
| Benzamides | 1 | 2019 | 1879 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 879 | 0.030 |
Why?
|
| Areca | 1 | 2013 | 2 | 0.030 |
Why?
|
| Lichen Planus, Oral | 1 | 2013 | 9 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2013 | 14639 | 0.030 |
Why?
|
| Texas | 1 | 2004 | 6445 | 0.030 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2019 | 742 | 0.030 |
Why?
|
| Leukoplakia, Oral | 1 | 2013 | 71 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 2032 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2013 | 6344 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2011 | 49 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2454 | 0.020 |
Why?
|
| Cricetinae | 1 | 2011 | 744 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2009 | 28 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 1250 | 0.020 |
Why?
|
| Hearing | 1 | 2009 | 67 | 0.020 |
Why?
|
| Cochlear Implants | 1 | 2009 | 48 | 0.020 |
Why?
|
| Cetuximab | 1 | 2010 | 474 | 0.020 |
Why?
|
| Health Services Research | 1 | 2009 | 232 | 0.020 |
Why?
|
| Nasal Polyps | 1 | 2007 | 29 | 0.020 |
Why?
|
| Basement Membrane | 1 | 2007 | 142 | 0.020 |
Why?
|
| Osteomyelitis | 1 | 2010 | 259 | 0.020 |
Why?
|
| Nasal Mucosa | 1 | 2007 | 82 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 212 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 7233 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2007 | 258 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 9464 | 0.020 |
Why?
|
| Taxoids | 1 | 2010 | 1019 | 0.020 |
Why?
|
| Stents | 1 | 2012 | 1001 | 0.020 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2006 | 142 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 4810 | 0.020 |
Why?
|
| Speech | 1 | 2006 | 142 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 5157 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 14886 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 4966 | 0.010 |
Why?
|
| Neck | 1 | 2006 | 394 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 15280 | 0.010 |
Why?
|
| Neoplasm Staging | 2 | 2009 | 14037 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2009 | 33860 | 0.010 |
Why?
|
| United States | 1 | 2020 | 15834 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 2006 | 530 | 0.010 |
Why?
|
| Sex Factors | 1 | 2008 | 2180 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 1825 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2009 | 39982 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 5146 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 2272 | 0.010 |
Why?
|
| Comorbidity | 1 | 2007 | 2393 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 4839 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 6193 | 0.010 |
Why?
|
| Prognosis | 2 | 2009 | 22533 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 32698 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 5443 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 3429 | 0.010 |
Why?
|
| Palliative Care | 1 | 2010 | 2177 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 4007 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2006 | 2124 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 5824 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 4470 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 9048 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 9054 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 61363 | 0.000 |
Why?
|